Ignyta RXDX results

RXDX phase 1 partial results announced. Still dose escalating. 11 patients with ALK alterations had been dosed (seven of whom had received prior treatment with crizotinib), 11 patients with ROS1 alterations had been dosed, two patients with TrkA alterations had been dosed.

No dose-limiting toxicities had been observed.

http://investor.ignyta.com/releasedetail.cfm?releaseid=873325

This entry was posted in RXDX-101 - entrectinib - by Ignyta. Bookmark the permalink.

Leave a Reply